The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024 - Scorecard - MDSpire

The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024

  • By

  • Madineh Abbasi

  • Ehsan Sheykh Noori

  • Faramarz Mobaraki

  • Omid Dehghan

  • Fatemeh Nikpour

  • Ahmad Raeisi

  • Abdolreza Mirolyaie

  • Mahasti Alizadeh

  • Ahmad Koosha

  • Saideh Yousefi

  • February 6, 2026

  • 0 min

Share

Clinical Scorecard: The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingHealthcare facilities capable of conducting dengue rapid diagnostic tests and providing supportive care.

Key Highlights

  • No universally approved treatment or vaccine exists for all age groups; some vaccines are available but not universally approved.

Guideline-Based Recommendations

Diagnosis

    Management

    • Focus on mosquito bite prevention as the primary control strategy.
    • Include supportive care management for symptomatic patients.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        No specific antiviral treatment; management is supportive, focusing on hydration and pain relief.

        Clinical Best Practices

        • Enhance knowledge, attitudes, and practices (KAP) among healthcare professionals through targeted training programs.
        • Strengthen vector control efforts to mitigate outbreaks.
        • Conduct epidemiological studies to inform public health strategies.

        References

        Original Source(s)

        The Rise of Indigenous Dengue Fever Cases in Iran: An In-Depth Examination of the Initial Significant Outbreak in Sistan and Baluchestan Province, 2024

        • by Madineh Abbasi, Ehsan Sheykh Noori, Faramarz Mobaraki, Omid Dehghan, Fatemeh Nikpour, Ahmad Raeisi, Abdolreza Mirolyaie, Mahasti Alizadeh, Ahmad Koosha, Saideh Yousefi

        • February 6, 2026

        Related Content

        The 18-Month MDR-TB Regimen Has a Successor

        Six months, all-oral, better tolerated—and the infrastructure to make it work.

        I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook

        RSV Prevention Tied to Lower Infant Acute Care Use

        Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.